SCHEMBL379800

SCHEMBL379800

c1ccc(CCCCNc2nccc3scc(-c4ccccc4)c23)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
LMNA P02545 3/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ESR1 P03372 2/20 0.42
GBA1 P04062 1/20 0.42
HPGD P15428 1/20 0.42
UTS2R Q9UKP6 1/20 0.41
TNF P01375 1/20 0.41
MAPK1 P28482 1/20 0.41
NOD1 Q9Y239 1/20 0.41
ASPH Q12797 1/20 0.40
KDM8 Q8N371 1/20 0.40
KDR P35968 3/20 0.40
HTT P42858 1/20 0.39
NCOA1 Q15788 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL380611 0.85 HPGD (0.43) LMNAGBA1HPGDUTS2RASPH
SCHEMBL379865 0.84 ESR1 (0.55) KDM4EALDH1A1LMNAESR1HPGD
SCHEMBL4946829 0.78 PDE11A (0.49) KDM4EALDH1A1LMNAESR1UTS2R
SCHEMBL379757 0.76 CCNC (0.47) ESR1HPGDUTS2RTNFMAPK1
SCHEMBL379602 0.76 PDE11A (0.47) KDM4EALDH1A1LMNAESR1UTS2R
SCHEMBL379387 0.76 TNF (0.69) ALDH1A1LMNASMN1; SMN2TNFMAPK1
SCHEMBL380011 0.75 UTS2R (0.53) KDM4EALDH1A1LMNASMN1; SMN2GBA1
SCHEMBL379745 0.74 EED (0.49) KDM4EALDH1A1LMNASMN1; SMN2ESR1
SCHEMBL379504 0.72 TNF (0.47) KDM4EALDH1A1RXFP1LMNAESR1
SCHEMBL2369595 0.72 MAPK1 (0.63) KDM4EALDH1A1RXFP1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP claimed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP claimed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US claimed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO claimed
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US disclosed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP disclosed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP disclosed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US disclosed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161672-A1 Compounds KCNJ2, KCNT1, KCNT2 KDM4E 1216/4885ALDH1A1 371/4885RXFP1 3094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.